CAJ | 학술논문

目的利用内镜超声观察PLGA-PEG-PLGA-5-氟尿嘧啶温敏水凝胶对胰腺癌进行的治疗效果.方法 (1) PLGA-PEG-PLGA-5-氟尿嘧啶温敏水凝胶的体外释放实验:测定不同时间点浸出液药物的浓度,计算释放量；(2)将胰腺癌细胞株SW1990皮下成瘤裸鼠50只随机分为5组,每组10只.A组瘤内注射PLGA-PEG-PLGA-5-氟尿嘧啶温敏水凝胶4 mg/kg;B组瘤内注射PLGA-PEG-PL-GA-5-氟尿嘧啶温敏水凝胶1mg/kg;C组瘤体内注射5-氟尿嘧啶注射液4 mg/kg;D组瘤体内注射瘤体内注射PLGA-PEG-PLGA基质4 mg/kg;E组为空白对照组.于给药前、给药后3、7、10、14 d应用内镜超声观察裸鼠肿瘤结节的生长及声像图,绘制肿瘤生长曲线；14 d时处死动物,称瘤重,计算抑瘤率；行HE染色,观察不同组病理结果.结果 (1)5-氟尿嘧啶温敏水凝胶药物释放率第1天为21.6％,第3天33.8％,第5天为44.3％,第8天为63.6％,第10天为76.3％,第14天为91.8％.(2)内镜超声测量不同时段瘤体大小,A组、B组瘤体与其他组相比明显缩小,差异具有统计学意义(P＜0.05).超声内镜下图像特点与病理结果具相关性.结论 PLGA-PEG-PLGA-5-氟尿嘧啶温敏水凝胶在14 d内能在体外较稳定地持续释放,对人胰腺癌细胞株SW1990有持续抑制作用.该剂瘤内注射可明显抑制胰腺癌瘤裸鼠瘤体的生长,凝胶状制剂较液态制剂在瘤体内固定性好,内镜超声监测下5-氟尿嘧啶温敏水凝胶间质化疗胰腺癌的操作方便、安全；PLGA-PEG-PLGA-5-氟尿嘧啶温敏水凝胶制剂具有一定的潜在临床应用价值.
목적 이용내경초성관찰PLGA-PEG-PLGA-5-불뇨밀정온민수응효대이선암진행적치료효과.방법 (1) PLGA-PEG-PLGA-5-불뇨밀정온민수응효적체외석방실험:측정불동시간점침출액약물적농도,계산석방량；(2)장이선암세포주SW1990피하성류라서50지수궤분위5조,매조10지.A조류내주사PLGA-PEG-PLGA-5-불뇨밀정온민수응효4 mg/kg;B조류내주사PLGA-PEG-PL-GA-5-불뇨밀정온민수응효1mg/kg;C조류체내주사5-불뇨밀정주사액4 mg/kg;D조류체내주사류체내주사PLGA-PEG-PLGA기질4 mg/kg;E조위공백대조조.우급약전、급약후3、7、10、14 d응용내경초성관찰라서종류결절적생장급성상도,회제종류생장곡선；14 d시처사동물,칭류중,계산억류솔；행HE염색,관찰불동조병리결과.결과 (1)5-불뇨밀정온민수응효약물석방솔제1천위21.6％,제3천33.8％,제5천위44.3％,제8천위63.6％,제10천위76.3％,제14천위91.8％.(2)내경초성측량불동시단류체대소,A조、B조류체여기타조상비명현축소,차이구유통계학의의(P＜0.05).초성내경하도상특점여병리결과구상관성.결론 PLGA-PEG-PLGA-5-불뇨밀정온민수응효재14 d내능재체외교은정지지속석방,대인이선암세포주SW1990유지속억제작용.해제류내주사가명현억제이선암류라서류체적생장,응효상제제교액태제제재류체내고정성호,내경초성감측하5-불뇨밀정온민수응효간질화료이선암적조작방편、안전；PLGA-PEG-PLGA-5-불뇨밀정온민수응효제제구유일정적잠재림상응용개치.
Objective To evaluate the therapeutic effect of PLGA-PEG-PLGA-5-fluorouracil temperature-sensitive hydrogel interstitial chemotherapy for pancreatic cancer by using endoscopic ultrasonography.Methods PLGA-PEG-PLGA-5-fluorouracil temperature-sensitive hydrogel in vitro release experiments were performed in the following procedures:determination of lixivium drug concentration and calculation of its emission.Fifty nude mice with the pancreatic cancer cell line SW1990 were randomly divided into 5 groups,10 in each group.Group A was intratumorally injected with PLGA-PEG-PLGA-5-fluorouracil temperature-sensitive hydrogel at 4mg/kg ; group B with PLGA-PEG-PLGA-5-fluorouracil temperature-sensitive hydrogel at lmg/kg; Group C was intratumorally injected with 5-fluorouracil at 4 mg/kg ; Group D with PLGAPEG-PLGA matrix at 4mg/kg ;and group E was the control group.Tumor growth and audio-visual images of the nude mice tumor nodules were observed before administration,and 3,7,10,14 days after.Tumor growth curve was also drawn.Animals were sacrificed at 14 days Tumors were weighed to calculate the inhibitory rate and stained for pathological study.Results 1,3,5,8,10,and 14-day release of 5-fluorouracil temperature-sensitive hydrogel were 21.6％,33.8 ％,44.3％,63.6％,76.3％ and 91.8％.Tumor sizes of group A and group B were significantly different from those of other groups (P ＜ 0.05).Ultrasound endoscopic image characteristics were correlated with pathological findings.Conclusion PLGA-PEG-PLGA-5-fluorouracil temperature-sensitive hydrogel is able to release for 14 days in vitro,which constantly inhibits human pancreatic cancer cell line SW1990.Intratumoral injection of the agent can significantly inhibit the growth of pancreatic cancer of nude mice.Additionally,gelatinous preparations fixes better than liquid and is of clinical value.Therefore,monitoring temperature-sensitive 5-fluorouracil hydrogel interstitial chemotherapy for pancreatic cancer with endoscopic ultrasound is convenient and safe.